Abstract
Prostate cancer is predicted to be the most common cancer diagnosed in American men in 2006 with an estimated 230,000 new cases in the United States alone [1]. It is likely to result in over 27,000 deaths in 2006, and the average male will have a one in six chance of developing this malady in his lifetime [1]. These statistics illustrate the need to have screening and treatment systems in place that possess both a high degree of sensitivity as well as proven effectiveness. With the recent strides made in the field of molecular and cellular biology, it is now possible to analyze and tailor treatments to an individuals tumor. As the methods of analysis become more refined, researchers are better able to sift through the vast amounts of data and hone in on promising new targets. Molecular prognostic markers are already beginning to appear as a result of modern genomic analysis, and more are on the way. These markers are appearing in a variety of pathways including signal transduction, apoptosis, cell cycle regulation, angiogenesis, and cell adhesion. The emergence of viable prognostic markers indicative of specific tumor types holds the potential of greatly improving cancer screening methods as well as overall patient survival.
Keywords: Prostate cancer, biomarkers, prognosis, treatment
Current Cancer Therapy Reviews
Title: Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Volume: 3 Issue: 1
Author(s): Gregory Saia, Min Zhang, Vincent Depalo, Tim Lautenschlager and Arnab Chakravarti
Affiliation:
Keywords: Prostate cancer, biomarkers, prognosis, treatment
Abstract: Prostate cancer is predicted to be the most common cancer diagnosed in American men in 2006 with an estimated 230,000 new cases in the United States alone [1]. It is likely to result in over 27,000 deaths in 2006, and the average male will have a one in six chance of developing this malady in his lifetime [1]. These statistics illustrate the need to have screening and treatment systems in place that possess both a high degree of sensitivity as well as proven effectiveness. With the recent strides made in the field of molecular and cellular biology, it is now possible to analyze and tailor treatments to an individuals tumor. As the methods of analysis become more refined, researchers are better able to sift through the vast amounts of data and hone in on promising new targets. Molecular prognostic markers are already beginning to appear as a result of modern genomic analysis, and more are on the way. These markers are appearing in a variety of pathways including signal transduction, apoptosis, cell cycle regulation, angiogenesis, and cell adhesion. The emergence of viable prognostic markers indicative of specific tumor types holds the potential of greatly improving cancer screening methods as well as overall patient survival.
Export Options
About this article
Cite this article as:
Saia Gregory, Zhang Min, Depalo Vincent, Lautenschlager Tim and Chakravarti Arnab, Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126647
DOI https://dx.doi.org/10.2174/157339407780126647 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Studies of Antioxidant Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Withdrawal Notice: Preparation and Applications of Glyconanoparticles
Current Drug Targets The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) UCLA’s Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology
Combinatorial Chemistry & High Throughput Screening Importance of Male Fertility Control in Family Planning
Endocrine, Metabolic & Immune Disorders - Drug Targets Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Nanotechnology Versus other Techniques in Improving Drug Dissolution
Current Pharmaceutical Design Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Electroporation in DNA Vaccination Protocols Against Cancer
Current Drug Metabolism Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry